Buclizine is a first-generation piperazine-derivative antihistamine (H1-receptor antagonist) with pronounced antiemetic, antinauseant, and mild sedative properties. It is structurally and pharmacologically related to cyclizine and meclizine. In the Indian market, it is primarily available as an oral syrup (6mg/5ml) and is widely used for the prevention and treatment of nausea, vomiting, and vertigo associated with various conditions, including motion sickness, Ménière's disease, and labyrinthitis. Its efficacy is attributed to its central anticholinergic and depressant action on the vestibular system and the chemoreceptor trigger zone (CTZ).
Adult: 6mg to 12mg (5ml to 10ml of syrup) two to three times daily. For motion sickness: 12mg (10ml) taken 30-60 minutes before travel.
Note: Shake the syrup well before use. Use the measuring cup or spoon provided. Can be taken with or without food. Taking with food may reduce gastric irritation. For motion sickness, take at least 30 minutes before anticipated travel.
Buclizine competitively antagonizes histamine at the H1-receptor sites. Its primary therapeutic effects (antiemetic, antivertigo) are mediated through central antimuscarinic (anticholinergic) actions. It inhibits acetylcholine in the vestibular nuclei and has a depressant effect on labyrinthine function and the chemoreceptor trigger zone (CTZ) in the medulla oblongata, which is sensitive to various emetic stimuli.
Pregnancy: Category B3 (Australian Category) / FDA Category not formally assigned. Animal studies are insufficient. Use during pregnancy only if clearly needed and potential benefit justifies potential risk to the fetus. Avoid in first trimester unless absolutely necessary.
Driving: ADVISE NOT TO DRIVE. Buclizine can cause significant drowsiness, dizziness, and blurred vision, impairing the ability to drive or operate machinery. Effect may persist into the next day.
| Alcohol, Benzodiazepines, Opioids, Barbiturates | Potentiation of CNS depression, increased sedation, impaired psychomotor performance. | Major |
| Other Anticholinergics (e.g., Atropine, Tricyclic Antidepressants, Antipsychotics) | Additive anticholinergic side effects (dry mouth, blurred vision, urinary retention, constipation, confusion). | Major |
| Monoamine Oxidase Inhibitors (MAOIs) e.g., Phenelzine, Tranylcypromine | Increased anticholinergic and CNS depressant effects. Risk of hypertensive crisis. | Major |
| CNS Stimulants (e.g., Amphetamines) | The sedative effect of buclizine may be antagonized. | Moderate |